Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Lidocaine 2% (preservative-free, without vasoconstrictor), Lidocaine 2% + Magnesium Sulfate 10% (combination).
- Who it may be relevant to
- Registry conditions: Myofascial Pain Dysfunction Syndrome. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Effect of Adding Magnesium Sulfate to Lidocaine in the Treatment of Myofascial Pain Dysfunction Syndrome Using Surface Electromyography (sEMG).(Randomized Clinical Trial)
Overview
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Detailed description
This randomized clinical trial aims to evaluate whether adding magnesium sulfate to lidocaine in trigger point injections provides better pain relief and muscle relaxation in patients with Myofascial Pain Dysfunction Syndrome (MPDS) compared to lidocaine alone.
Participants diagnosed with MPDS will be randomly assigned into one of two groups:
Group 1 (Control Group): Trigger point injection of lidocaine 2% Group 2 (Intervention Group): Trigger point injection of lidocaine 2% combined with magnesium sulfate 10% Each participant will receive injections in the identified myofascial trigger points. Pain during injection and after injection will be assessed using the Visual Analog Scale (VAS). Muscle activity will be measured using surface electromyography (sEMG) at specific time points during rest and muscle contraction.
The study will compare the changes in pain scores and EMG readings between the two groups to determine whether magnesium sulfate enhances the analgesic and muscle-relaxing effects of lidocaine. The results of this study may help improve treatment strategies for MPDS and provide evidence for using magnesium sulfate as an adjuvant to lidocaine in trigger point injections.
Interventions
- Drug Lidocaine 2% (preservative-free, without vasoconstrictor)
Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor, 1.8 ml at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly. - Drug Lidocaine 2% + Magnesium Sulfate 10% (combination)
Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor mixed with 10%magnesium sulphate , Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄) at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.
Primary outcome measures
- Pain reduction. [Time frame: Baseline, 1week, 2 weeks post-injection.]
- Muscle activity improvement. [Time frame: Baseline, 1 week, 2 weeks post-injection]
Secondary outcome measures (1)
- Pain experienced during injection [Time frame: Immediately after injection]
Eligibility criteria
Inclusion criteria
- Age between 18 and 70 years.
- Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
- Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
- Pain duration ≥ 3 months.
- Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
- Noprior trigger point injection in the affected area within the past 3 months.
- Ability and willingness to provide informed consent.
- Compliance with study visits and procedures
Exclusion criteria
- Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
- Current use of anticoagulants or history of bleeding disorders.
- Systemic or local infection at or near the injection site.
- History of fibromyalgia, central pain syndromes, or cancer-related pain.
- Major psychiatric illnesses (e.g., schizophrenia, severe depression).
- Recent surgery or trauma to the head, neck, or upper back (<6 months).
- Use of analgesics (NSAIDs, opioids) within 5 days before intervention.
- Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Faculty of oral and dental medicine, cairo university — Giza
Publications
- Leitch J, Webb A, Pudwell J, Chamberlain S, Henry R, Nitsch R. Magnesium-Based Trigger Point Infiltrations Versus Local Anaesthetic Infiltrations in Chronic Pelvic Myofascial Pain: A Randomized, Double-Blind, Controlled Study. J Obstet Gynaecol Can. 2022 Aug;44(8):877-885. doi: 10.1016/j.jogc.2022.02.129. Epub 2022 Mar 24. PMID 35339694
- Refahee SM, Mahrous AI, Shabaan AA. Clinical efficacy of magnesium sulfate injection in the treatment of masseter muscle trigger points: a randomized clinical study. BMC Oral Health. 2022 Sep 19;22(1):408. doi: 10.1186/s12903-022-02452-3. PMID 36123724
Identifiers
NCT: NCT07390851 · CU-OMFS-MPDS-TP-2025